awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38932150-839503F4-8A81-461C-B8CF-1CD7730A7B99
Q38932150-839503F4-8A81-461C-B8CF-1CD7730A7B99
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38932150-839503F4-8A81-461C-B8CF-1CD7730A7B99
Biosimilars and the extrapolation of indications for inflammatory conditions.
P2860
Q38932150-839503F4-8A81-461C-B8CF-1CD7730A7B99
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38932150-839503F4-8A81-461C-B8CF-1CD7730A7B99
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9270bb7ae4bc7c42f3b42b101ec3f8b0e001fa1c
P2860
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.